ChemWerth manufacturing partner in China passes FDA inspection

Published: 10-Jul-2009

One of ChemWerth's manufacturing partners in China, Wuhan Pharmaceutical Factory, has passed an FDA overseas inspection.


One of ChemWerth's manufacturing partners in China, Wuhan Pharmaceutical Factory, has passed an FDA overseas inspection.

ChemWerth, a US developer of generic active pharmaceutical ingredients (APIs), and Wuhan are collaborating to develop APIs for the US and other regulated markets overseas. Wuhan continues to be a primary supplier of high quality APIs to the Chinese and US markets.

ChemWerth is committed to providing its customers with high quality products and ensuring that the manufacturing companies it works with are compliant with FDA regulations.

The company has been working with the FDA in China for more than 25 years and has been through approximately 100 FDA inspections.

"Our regulatory expertise in helping manufacturers like Wuhan get approved is a real value-added benefit for our customers," said ChemWerth ceo Peter Werth.

ChemWerth specialises in oral, injectable, topical and veterinary products. It represents numerous FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like